NASDAQ:AARD Aardvark Therapeutics (AARD) Stock Price, News & Analysis $0.92 -0.08 (-8.10%) Closing price 03:57 PM EasternExtended Trading$0.94 +0.02 (+2.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Aardvark Therapeutics Stock (NASDAQ:AARD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aardvark Therapeutics alerts:Sign Up Key Stats Today's Range$0.90▼$1.0650-Day Range$0.91▼$5.7552-Week Range$0.90▼$16.60Volume201,110 shsAverage Volume362,893 shsMarket Capitalization$20.12 millionP/E RatioN/ADividend YieldN/APrice Target$11.06Consensus RatingHold Company Overview Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity. Aardvark’s work centers on developing treatments for metabolic conditions with limited therapeutic options. Its investigational candidates are still in development and are not approved medicines.AI Generated. May Contain Errors. Read More Aardvark Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreAARD MarketRank™: 3.141780821915 of 5 starsAardvark Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 293rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialAardvark Therapeutics has a consensus price target of $11.06, representing about 1,088.2% upside from its current price of $0.93.Amount of Analyst CoverageAardvark Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aardvark Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.17) to ($2.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aardvark Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aardvark Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAardvark Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.78% of the float of Aardvark Therapeutics has been sold short.Short Interest Ratio / Days to CoverAardvark Therapeutics has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aardvark Therapeutics has recently increased by 87.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAardvark Therapeutics does not currently pay a dividend.Dividend GrowthAardvark Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.24 News SentimentAardvark Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aardvark Therapeutics this week, compared to 8 articles on an average week.Search Interest3 people have searched for AARD on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Aardvark Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394,930.00 in company stock.Percentage Held by Insiders17.80% of the stock of Aardvark Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAardvark Therapeutics has minimal institutional ownership at this time.Read more about Aardvark Therapeutics' insider trading history. Receive AARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Stock News HeadlinesAnalysts Offer Insights on NA Companies: Mobility Global Inc (MBGL) and Aardvark Therapeutics, Inc. (AARD)November 17 at 7:35 AM | theglobeandmail.comAardvark Therapeutics (NASDAQ:AARD) Announces Quarterly Earnings ResultsNovember 15, 2026 | americanbankingnews.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 20 at 1:00 AM | Reagan Gold Group (Ad)Aardvark Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 14, 2026 | marketscreener.comMAardvark Therapeutics (NASDAQ:AARD) Stock Dropped to "Strong Sell" by Wall Street ZenNovember 14, 2026 | americanbankingnews.comAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 13, 2026 | globenewswire.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Stock Has Consensus Price Target of $11.56November 12, 2026 | americanbankingnews.comAardvark Therapeutics consensus price target decreased 26.96% to $10.65November 2, 2026 | msn.comSee More Headlines AARD Stock Analysis - Frequently Asked Questions How have AARD shares performed this year? Aardvark Therapeutics' stock was trading at $13.13 at the beginning of 2026. Since then, AARD shares have decreased by 92.9% and is now trading at $0.9310. How were Aardvark Therapeutics' earnings last quarter? Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its quarterly earnings results on Friday, November, 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.19. When did Aardvark Therapeutics IPO? Aardvark Therapeutics (AARD) raised $100 million in an initial public offering (IPO) on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO. Who are Aardvark Therapeutics' major shareholders? Top institutional investors of Aardvark Therapeutics include Marshall Wace LLP (0.60%), State Street Corp (0.26%), Empowered Funds LLC (0.11%) and Ieq Capital LLC (0.05%). Insiders that own company stock include Tien-Li Lee and Nelson Sun. View institutional ownership trends. How do I buy shares of Aardvark Therapeutics? Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/13/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, AARD's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AARD Previous SymbolNASDAQ:AARD CIK1774857 Webaardvarktherapeutics.com Phone(858) 225-7696FaxN/AEmployees28Year Founded2017Price Target and Rating Average Price Target for Aardvark Therapeutics$11.06 High Price Target$47.00 Low Price Target$2.00 Potential Upside/Downside+1,103.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.27% Return on Assets-80.39% Debt Debt-to-Equity RatioN/A Current Ratio9.11 Quick Ratio12.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book0.35Miscellaneous Outstanding Shares21,890,000Free Float17,994,000Market Cap$20.12 million OptionableOptionable Beta4.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AARD) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.